Asia Pacific

Europe, Middle East & Africa (EMEA)

Latin America

North America
  • Home
  • Congress & Events
  • A Phase Ib Study to Evaluate RO7198457, an Individualized Neoantigen Specific Immunotherapy (iNeST), in Combination With Atezolizumab▼ in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase Ib Study to Evaluate RO7198457, an Individualized Neoantigen Specific Immunotherapy (iNeST), in Combination With Atezolizumab▼ in Patients With Locally Advanced or Metastatic Solid Tumors

RO7198457 is a systemically administered RNA-lipoplex individualized neoantigen specific immunotherapy (iNeST) designed to stimulate T cell responses against neoantigens. A first-in-human Phase Ib study of RO7198457, in combination with the aPD-L1 antibody atezolizumab▼ is being conducted in patients with locally advanced or metastatic solid tumors. Safety, tolerability, pharmacodynamic activity, and preliminary anti-tumor activity are presented in this oral presentation.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Send Via Email

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site Stay on Medically

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically